期刊
NATURE IMMUNOLOGY
卷 7, 期 12, 页码 1293-1298出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ni1399
关键词
-
类别
资金
- NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline
- NIAID NIH HHS [T32 AI07407, AI18697, R01 AI018697] Funding Source: Medline
- NIGMS NIH HHS [GM64750] Funding Source: Medline
CD23, the low-affinity immunoglobulin E receptor, is an important modulator of the allergic response and of diseases such as rheumatoid arthritis. The proteolytic release of CD23 from cells is considered a key event in the allergic response. Here we used loss-of-function and gain-of-function experiments with cells lacking or overexpressing candidate CD23-releasing enzymes (ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, ADAM19 and ADAM33), ADAM-knockout mice and a selective inhibitor to identify ADAM10 as the main CD23-releasing enzyme in vivo. Our findings provide a likely target for the treatment 5 of allergic reactions and set the stage for further studies of the involvement of ADAM10 in CD23-dependent pathologies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据